| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/08/2001 | CA2323183A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2170289C A method of treating liver disease and like indications with vasodilating agents |
| 05/08/2001 | CA2032141C Pharmaceutically active agents that impede amyloid formation in vivo |
| 05/03/2001 | WO2001031580A2 Methods and devices for identifying patterns in biological systems |
| 05/03/2001 | WO2001031054A1 Method of screening for inhibitors of asp1 |
| 05/03/2001 | WO2001031029A2 Human sphingosine kinase gene |
| 05/03/2001 | WO2001031016A2 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | WO2001031007A2 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/03/2001 | WO2001030987A2 Tankyrase h, compositions involved in the cell cycle and methods of use |
| 05/03/2001 | WO2001030969A2 Stanniocalcin proteins and nucleic acids and methods based thereon |
| 05/03/2001 | WO2001030848A2 Nucleic acids of the human abc1 gene and applications thereof |
| 05/03/2001 | WO2001030845A1 Pablo, a polypeptide that interacts with bcl-xl, and uses related thereto |
| 05/03/2001 | WO2001030844A1 Dna encoding human alpha1g-c t-type calcium channel |
| 05/03/2001 | WO2001030828A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |
| 05/03/2001 | WO2001030811A2 Complex comprising an igfiie polypeptide-fragment and an igfbp2 polypeptide and its use in the treatment of osteoporosis |
| 05/03/2001 | WO2001030798A1 Transgenic mice containing trp gene disruptions |
| 05/03/2001 | WO2001030789A1 Ruthenium (ii) complexes with high antitumoral and antimetastatic activities |
| 05/03/2001 | WO2001030448A1 Method and compositions for administering taxanes orally to human patients |
| 05/03/2001 | WO2001030394A1 Treatment of cancer |
| 05/03/2001 | WO2001030393A2 Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products |
| 05/03/2001 | WO2001030392A2 Delivery of proteins across polar epithelial cell layers |
| 05/03/2001 | WO2001030386A1 Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye |
| 05/03/2001 | WO2001030383A2 Medicament in order to induce tolerance |
| 05/03/2001 | WO2001030381A2 Use of csf-1 inhibitors |
| 05/03/2001 | WO2001030379A2 Compositions and methods for preventing and treating transplant rejection |
| 05/03/2001 | WO2001030378A1 A method of prophylaxis and treatment |
| 05/03/2001 | WO2001030375A2 Use of gdnf for treating corneal defects |
| 05/03/2001 | WO2001030362A2 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 05/03/2001 | WO2001030357A1 Hormonal composition based on a progesterone and an oestrogen and use thereof |
| 05/03/2001 | WO2001030356A1 Hormonal composition based on a progestational agent and an oestrogen and use thereof |
| 05/03/2001 | WO2001030353A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 05/03/2001 | WO2001030352A1 High dose folic acid for the treatment of hyperhomocysteinemia |
| 05/03/2001 | WO2001030350A1 Treating sleep disorders using desloratadine |
| 05/03/2001 | WO2001030346A1 Treatment of dyskinesia |
| 05/03/2001 | WO2001030345A1 Clonidine preparations |
| 05/03/2001 | WO2001030344A1 Indole-3-carbinol (i3c) derivatives |
| 05/03/2001 | WO2001030343A1 Pharmaceuticals for treating obesity |
| 05/03/2001 | WO2001030342A1 Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
| 05/03/2001 | WO2001030333A2 Tissue factor antagonists and methods of use thereof |
| 05/03/2001 | WO2001030332A2 Methods of protecting neuronal function |
| 05/03/2001 | WO2001030331A2 Therapeutic compositions including protein kinase c inhibitors |
| 05/03/2001 | WO2001030329A2 Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction |
| 05/03/2001 | WO2001030326A1 Treatment of emphysema using rar selective retinoid agonists |
| 05/03/2001 | WO2001030323A2 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 05/03/2001 | WO2001030300A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | WO2001030287A1 Local prevention or amelioration of pain from surgically closed wounds |
| 05/03/2001 | WO2001030148A1 Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections |
| 05/03/2001 | WO2001016164A3 Treatment of allergic rhinitis |
| 05/03/2001 | WO2001005968A9 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 05/03/2001 | WO2001000221A3 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 05/03/2001 | WO2000077168A3 ANTAGONISTS OF BMP AND TGFβ SIGNALLING PATHWAYS |
| 05/03/2001 | WO2000072876A3 Prevention and treatment of amyloidogenic disease |
| 05/03/2001 | WO2000066164A8 Contraceptive compositions containing antiprogestinic and progestinic |
| 05/03/2001 | WO2000066107A3 Antimalarian agents for the treatment of asthma |
| 05/03/2001 | WO2000054785A3 Stabilized bicyclo[3.3.1]nonenes and methods of use |
| 05/03/2001 | US20010000785 Attaching a bioeffecting agent to a substrate with an anchor provided by a linker compound which also forms a cleavable linkage so that the drug has a sustained release; anti-thrombogenic, -imicrobial, -inflammatory agents |
| 05/03/2001 | US20010000783 Associated with inhibited epithelial cell proliferation comprising administering a heparin-binding epidermal growth factor-like growth factor (HB-EGF) or derivative, e,g. anantiidiotypic antibody to HB-EGF, gene therapy; angonists |
| 05/03/2001 | US20010000730 Method of enhancing the efficacy of anti-tumor agents |
| 05/03/2001 | DE19951970A1 Arzneimittel für die Toleranzinduktion Medicines for tolerance induction |
| 05/03/2001 | DE19949179A1 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse Nucleic acid sequences of hyperplasias and tumors of the thyroid |
| 05/03/2001 | DE10038203A1 Implantable active agent depot, useful e.g. in local tumor treatment or gene therapy, comprising drug-containing, cubic phase forming lipid matrix containing modifier molecule to control release kinetics |
| 05/03/2001 | CA2389583A1 Method and compositions for administering taxanes orally to human patients |
| 05/03/2001 | CA2389171A1 Ruthenium (ii) complexes with high antitumoral and antimetastatic activities |
| 05/03/2001 | CA2389127A1 Human sphingosine kinase gene |
| 05/03/2001 | CA2389031A1 Dna encoding human alpha1g-c t-type calcium channel |
| 05/03/2001 | CA2388998A1 Treatment of cancer |
| 05/03/2001 | CA2388974A1 Medicament in order to induce tolerance |
| 05/03/2001 | CA2388950A1 Nucleic acids of the human abc1 gene and their therapeutic and diagnostic application |
| 05/03/2001 | CA2388942A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |
| 05/03/2001 | CA2388924A1 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 05/03/2001 | CA2388617A1 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/03/2001 | CA2388338A1 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | CA2388332A1 Tankyrase h, compositions involved in the cell cycle and methods of use |
| 05/03/2001 | CA2388298A1 The use of csf-1 inhibitors |
| 05/03/2001 | CA2387897A1 Complex comprising an igfiie polypeptide-fragment and an igfbp2 polypeptide and its use in the treatment of osteoporosis |
| 05/03/2001 | CA2387889A1 Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye |
| 05/03/2001 | CA2387857A1 Tissue factor antagonists and methods of use thereof |
| 05/03/2001 | CA2387685A1 Stanniocalcin proteins and nucleic acids and methods based thereon |
| 05/03/2001 | CA2387680A1 Pablo, a polypeptide that interacts with bcl-xl, and uses related thereto |
| 05/03/2001 | CA2387652A1 A method of prophylaxis and treatment |
| 05/03/2001 | CA2387378A1 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | CA2386908A1 Treating sleep disorders using desloratadine |
| 05/03/2001 | CA2386750A1 Pharmaceuticals for treating obesity |
| 05/03/2001 | CA2385929A1 Use of gdnf for treating corneal defects |
| 05/02/2001 | EP1096008A2 Human G protein-coupled receptor, PFI-014 |
| 05/02/2001 | EP1095661A1 Prevention and treatment of biomaterial-associated infections |
| 05/02/2001 | EP1095655A2 NK-1 receptor antagonists and eletriptan for the treatment of migraine |
| 05/02/2001 | EP1095279A1 Method for identifying a presenilinase inhibitor |
| 05/02/2001 | EP1095275A2 Endogenous constitutively activated g protein-coupled orphan receptors |
| 05/02/2001 | EP1095274A1 Trifunctional reagent for conjugation to a biomolecule |
| 05/02/2001 | EP1095183A2 Methods for the diagnosis and treatment of lung cancer |
| 05/02/2001 | EP1095148A2 Cloning and characterisation of novel mammalian peptidases |
| 05/02/2001 | EP1095142A2 Molecules associated with cell proliferation |
| 05/02/2001 | EP1095136A1 Cells and animals deficient in protein kinase c epsilon |
| 05/02/2001 | EP1095062A1 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| 05/02/2001 | EP1095050A1 Phosphorous organic compounds and their use |
| 05/02/2001 | EP1095020A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 05/02/2001 | EP1094840A1 Use of texaphyrins in macrophage-mediated disease |
| 05/02/2001 | EP1094832A1 Therapeutic use of uncoupling protein-hhfcw60 |
| 05/02/2001 | EP1094831A1 Compositions and methods for in vitro fertilization |